Asset profile
Rybrevant Faspro (amivantamab and hyaluronidase-lpuj)
Multispecific antibody
Evidence outlook
Approved: Non-Small Cell Lung Cancer
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
68 competitors in this universe: 8 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Rybrevant Faspro (amivantamab And Hyaluronidase-Lpuj): this drug | Approved | Multispecific antibody | EGFR x c-MET | ||
| Amivantamab | Approved | Multispecific antibody | EGFR x c-MET | ||
| ALK202 | Phase 2 | Small molecule | EGFR x c-MET | ||
| EMB-01 | Phase 2 | Multispecific antibody | EGFR x c-MET | ||
| MCLA-129 | Phase 2 | Multispecific antibody | EGFR x c-MET | ||
| SKB571 For | Phase 2 | Antibody–drug conjugate | EGFR x c-MET | ||
| 225Ac-FPI-2068 | Phase 1 | Radiopharmaceutical | EGFR x c-MET | ||
| AZD9592 | Phase 1 | Antibody–drug conjugate | EGFR x c-MET | ||
| QLS5316 | Phase 1 | Small molecule | EGFR x c-MET | ||
| Afatinib (Gilotrif) | Approved | Small molecule | EGFR/HER1, HER2, HER4 | ||
| Alectinib (Alecensa) | Approved | Small molecule | ALK | ||
| Alymsys (bevacizumab-Maly) | Approved | Monoclonal antibody | VEGF-A | ||
| Atezolizumab | Approved | Monoclonal antibody | PD-L1 | ||
| BAT1706 (Avzivi) | Approved | Monoclonal antibody | VEGF-A | ||
| BAY2927088 (Hyrnuo) | Approved | Small molecule | HER2 (ERBB2) exon 20 insertions and point mutations; also mutant-selective EGFR | ||
| Bevacizumab | Approved | Monoclonal antibody | VEGF-A, Vascular Endothelial Growth Factor Inhibitor |
…and 53 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.